Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 May 2017
At a glance
- Drugs GL 0817 (Primary) ; Lenalidomide; Poly ICLC
- Indications Myeloma
- Focus Therapeutic Use
- 01 May 2017 Planned End Date changed from 1 Nov 2013 to 1 Dec 2017.
- 01 May 2017 Planned primary completion date changed from 1 Nov 2013 to 1 Aug 2017.
- 14 Dec 2015 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.